Literature DB >> 17034996

Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations.

Stefanie Schüle1, Wolfgang Friess, Karoline Bechtold-Peters, Patrick Garidel.   

Abstract

Inhalation of spray-dried particles is a promising delivery route for proteins as an alternative to injection. Changes in the protein structure and aggregation have to be avoided. The effect of mannitol, a stabilizing agent typically used in both liquid and lyophilized protein formulations, on an antibody (IgG1) in a spray-dried powder was studied using different biophysical and chromatographic techniques. At first, different solutions composed of antibody (IgG1) and mannitol at a ratio between 20/80 and 100/0 IgG1/mannitol (100 mg/ml total solid) were investigated for their stability. Protein solutions containing the IgG1 showed mannitol-dependent aggregation. High amounts of mannitol (50-80%) exerted a destabilizing effect on the antibody and the aggregate 9 level increased to 2.6-4.2%. In contrast, solutions with only 20-40% mannitol showed the same amount of aggregates as the pure antibody solution. The antibody mannitol solutions were investigated by circular dichroism (CD) and Fourier transform infrared spectroscopy (FTIR) to evaluate whether changes in the protein secondary structure can be correlated with aggregation. Considering the sensitivity of the used methods and data evaluation, FTIR spectra did not reveal structural changes in the IgG1/mannitol solutions compared to the pure antibody, despite varying aggregate levels. Thermal stress was reflected in perturbations of the secondary structure, but mannitol-dependent aggregation could not be correlated to detectable alterations in the FTIR spectra. Analyzing the CD spectra revealed no distinctive change in the shape of the CD curve, indicating that the protein secondary structure is mainly retained. This is in agreement with the infrared data. Subsequently, the IgG1/mannitol solutions were spray-dried at Tin/Tout of 90/50 degrees C. Using ATR-FTIR for the investigation of the protein amide I band in the spray-dried powder revealed changes in the sub-components of the amide I band. This indicates that the peptide groups (CO and NH) of the protein are found in a different environment in the solid state, compared to the liquid protein formulation. After redissolution of the powders, the native structure of the pure antibody solution was found identical to the protein secondary structure before spray-drying, indicating that the protein secondary structure is not strongly altered in the dry state, and not affected by the spray-drying process. Thus, from the presented study it can be concluded that the formation of antibody aggregates in mannitol formulations cannot be correlated with significant perturbations of the protein secondary structure elements.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17034996     DOI: 10.1016/j.ejpb.2006.08.014

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  20 in total

1.  Insights into protein-polysorbate interactions analysed by means of isothermal titration and differential scanning calorimetry.

Authors:  Claudia Hoffmann; Alfred Blume; Inge Miller; Patrick Garidel
Journal:  Eur Biophys J       Date:  2009-02-03       Impact factor: 1.733

2.  Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions.

Authors:  Srivalli N Telikepalli; Ozan S Kumru; Cavan Kalonia; Reza Esfandiary; Sangeeta B Joshi; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2014-01-22       Impact factor: 3.534

Review 3.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

4.  Effect of pH and excipients on structure, dynamics, and long-term stability of a model IgG1 monoclonal antibody upon freeze-drying.

Authors:  Jihea Park; Karthik Nagapudi; Camille Vergara; Ranjini Ramachander; Jennifer S Laurence; Sampathkumar Krishnan
Journal:  Pharm Res       Date:  2012-11-27       Impact factor: 4.200

5.  Rapid, quantitative determination of aggregation and particle formation for antibody drug conjugate therapeutics with label-free Raman spectroscopy.

Authors:  Chi Zhang; Jeremy S Springall; Xiangyang Wang; Ishan Barman
Journal:  Anal Chim Acta       Date:  2019-07-10       Impact factor: 6.558

6.  Effects of Drying Process on an IgG1 Monoclonal Antibody Using Solid-State Hydrogen Deuterium Exchange with Mass Spectrometric Analysis (ssHDX-MS).

Authors:  Ehab M Moussa; Nathan E Wilson; Qi Tony Zhou; Satish K Singh; Sandeep Nema; Elizabeth M Topp
Journal:  Pharm Res       Date:  2018-01-03       Impact factor: 4.200

7.  Stable dry powder formulation for nasal delivery of anthrax vaccine.

Authors:  Sheena H Wang; Shaun M Kirwan; Soman N Abraham; Herman F Staats; Anthony J Hickey
Journal:  J Pharm Sci       Date:  2011-09-08       Impact factor: 3.534

8.  Effects of drying method and excipient on structure and stability of protein solids using solid-state hydrogen/deuterium exchange mass spectrometry (ssHDX-MS).

Authors:  Nathan E Wilson; Elizabeth M Topp; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2019-06-25       Impact factor: 5.875

9.  Impact of crystalline and amorphous matrices on successful spray drying of siRNA polyplexes for inhalation of nano-in-microparticles.

Authors:  Tobias Wm Keil; Christoph Zimmermann; Domizia Baldassi; Friederike Adams; Wolfgang Friess; Aditi Mehta; Olivia M Merkel
Journal:  Adv Ther (Weinh)       Date:  2021-05-07

10.  Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization.

Authors:  Agnès Maillet; Nicolas Congy-Jolivet; Sandrine Le Guellec; Laurent Vecellio; Sophie Hamard; Yves Courty; Anthony Courtois; Francis Gauthier; Patrice Diot; Gilles Thibault; Etienne Lemarié; Nathalie Heuzé-Vourc'h
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.